Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100938 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTSTS | |
| SCHEMBL20100934 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AHTTSTS | |
| SCHEMBL20100953 | 0.84 | CYP2D6 (0.36) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL20100954 | 0.83 | CYP2D6 (0.47) | SMN1; SMN2NPC1RAB9AMAPTL3MBTL1 | |
| SCHEMBL17941263 | 0.77 | KMT2A (0.45) | SMN1; SMN2NPC1RAB9AHTTSTS | |
| SCHEMBL17941237 | 0.76 | STS (0.46) | SMN1; SMN2NPC1RAB9AHTTSTS | |
| SCHEMBL17941240 | 0.76 | STS (0.46) | SMN1; SMN2NPC1RAB9AHTTSTS | |
| SCHEMBL17941244 | 0.72 | ALOX15 (0.40) | SMN1; SMN2NPC1RAB9AHTTSTS | |
| SCHEMBL17941239 | 0.72 | POLB (0.60) | SMN1; SMN2MAPTL3MBTL1CYP2C19 | |
| SCHEMBL17941233 | 0.71 | SERPINE1 (0.45) | SMN1; SMN2NPC1RAB9AHTTSTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | XIAMEN UNIVERSITY (CN) | 2018-05-03 | — | — | US | disclosed |
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | XIAMEN UNIVERSITY (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180116993-A1 | MODULATORS OF FARNESOID X RECEPTOR AND METHODS FOR THE USE THEREOF | NR1H4, FABP1, NR1H2 | SMN1; SMN2 4843/4885NPC1 126/4885RAB9A 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.